Paula L. R.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase II Multicenter Trial of Patritumab Deruxtecan in HER3-Expressing Advanced Breast and Non-Small Cell Lung Cancer with Brain Metastases and Leptomeningeal Carcinomatosis
- Phase 3 Randomized Study of GLSI-100 (GP2 + Sargramostim) in HER2/neu Positive Breast Cancer with Residual Disease or High-Risk PCR Post-Trastuzumab Therapy
- Evaluation of Diarrhea-Related Discontinuations in Early-Stage HER2+/HR+ Breast Cancer with Neratinib, Loperamide, and Colesevelam Prophylaxis
Data & Insights
Has run more than one trial at 30 of 193 partner sites.
Specializations
Breast Cancer Specialization
This investigator focuses on advanced therapeutic approaches for HER2-positive breast cancer, particularly in cases involving residual disease and high-risk conditions following standard treatments.
- Early-stage breast cancer management
- HER2/neu positive breast cancer therapy
- Post-neoadjuvant treatment strategies
The research extends to patients who have completed trastuzumab-based therapy regimens.
Targeted Therapies
Expertise in developing and evaluating targeted therapeutic approaches for specific breast cancer subtypes, with particular attention to hormone receptor-positive cases.
- HER2-targeted treatments
- Hormone receptor-positive therapy
- Peptide-based interventions
The investigator specializes in treatment optimization for patients with specific molecular profiles.
Treatment Management
Focus on treatment tolerability and management of therapy-related complications in breast cancer patients undergoing targeted treatments.
- Side effect management
- Treatment discontinuation prevention
- Supportive care strategies
Emphasis on developing protocols to improve treatment adherence and patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.